SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-24-092551 from Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics, Inc.
Date: April 11, 2024 · CIK: 0001907108 · Accession: 0001193125-24-092551

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-278566

Date
April 11, 2024
Author
Jenny R. Robertson
Form
CORRESP
Company
Lexeo Therapeutics, Inc.

Letter

April 11, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Office of Life Sciences

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attn: Tamika Sheppard

Re: Lexeo Therapeutics, Inc.

Registration Statement on Form S-1

File No. 333-278566

Acceleration Request

Requested Date: April 12, 2024

Requested Time: 4:30 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-278566) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan Baier at (312) 636-2073.

Sincerely,
LEXEO THERAPEUTICS, INC.

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 April 11, 2024

VIA EDGAR

 U.S. Securities and Exchange Commission

Office of Life Sciences

 Division of Corporation Finance

100 F Street, N.E.

 Washington, D.C. 20549-3720

Attn: Tamika Sheppard

Re:
 Lexeo Therapeutics, Inc.

Registration Statement on Form S-1

File No. 333-278566

Acceleration Request

 Requested Date:
April 12, 2024

 Requested Time: 4:30 P.M. Eastern Time

Ladies and Gentlemen:

 Pursuant to Rule 461 under the Securities
Act of 1933, as amended, Lexeo Therapeutics, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File
No. 333-278566) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company
or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with
our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Megan Baier at (312) 636-2073.

Sincerely,

LEXEO THERAPEUTICS, INC.

/s/ Jenny R. Robertson

Jenny R. Robertson

Chief Business and Legal Officer

cc:
 R. Nolan Townsend

Lexeo Therapeutics, Inc.

Megan J. Baier

 David G. Sharon

 Wilson Sonsini Goodrich & Rosati, P.C.